Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Accolade | ACCD | Feb 6, 2025 | 6.88 | -0.29 |
Accuray | ARAY | Feb 6, 2025 | 2.69 | +8.03 |
Acelyrin | SLRN | Feb 6, 2025 | 1.90 | -2.06 |
Achieve Life Sciences | ACHV | Feb 6, 2025 | 3.21 | -4.75 |
Achilles Therapeutics ADR | ACHL | Feb 6, 2025 | 1.39 | 0.00 |
ACI Worldwide | ACIW | Feb 6, 2025 | 54.03 | -1.46 |
Aclarion | ACON | Feb 6, 2025 | 6.27 | -3.69 |
Aclaris Therapeutics | ACRS | Feb 6, 2025 | 2.43 | -5.45 |
ACM Research A | ACMR | Feb 6, 2025 | 23.01 | +10.36 |
Acme United | ACU | Feb 6, 2025 | 38.11 | +1.63 |
ACNB | ACNB | Feb 6, 2025 | 41.01 | +0.39 |
ACRES Commercial Realty | ACR | Feb 6, 2025 | 18.40 | +1.04 |
ACRES Commercial Realty C Pref | ACR-C | Feb 6, 2025 | 25.01 | -0.08 |
ACRES Commercial Realty D Pref | ACR-D | Feb 6, 2025 | 22.35 | +0.22 |
Acrivon Therapeutics | ACRV | Feb 6, 2025 | 6.51 | -6.60 |
Actelis Networks | ASNS | Feb 6, 2025 | 1.25 | +3.31 |
Actinium Pharmaceuticals | ATNM | Feb 6, 2025 | 1.15 | -6.50 |
Active Bear ETF | HDGE | Feb 6, 2025 | 15.95 | +0.76 |
Active U.S. Real Estate Powershares | PSR | Feb 6, 2025 | 92.31 | +0.49 |
Actuate Therapeutics | ACTU | Feb 6, 2025 | 8.82 | -6.56 |
Acuity Brands | AYI | Feb 6, 2025 | 328.72 | +1.42 |
Acumen Pharmaceuticals | ABOS | Feb 6, 2025 | 1.47 | -4.55 |
Acurx Pharmaceuticals | ACXP | Feb 6, 2025 | 0.78 | -1.70 |
Acushnet | GOLF | Feb 6, 2025 | 65.71 | +0.83 |
ACV Auctions A | ACVA | Feb 6, 2025 | 20.97 | +0.62 |
ACWI Ex-US Index MSCI Ishares | ACWX | Feb 6, 2025 | 54.74 | +0.40 |
ACWI Index MSCI Ishares | ACWI | Feb 6, 2025 | 122.31 | +0.34 |
Adagene ADR | ADAG | Feb 6, 2025 | 1.78 | -1.65 |
Adagio Medical | ADGM | Feb 6, 2025 | 1.08 | -1.82 |
Adams Diversified Equity Fund | ADX | Feb 6, 2025 | 20.65 | +0.15 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.